Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients

Author:

Lobet Sarah1,Caulet Morgane2,Paintaud Gilles34,Azzopardi Nicolas5,Desvignes Céline34,Chautard Romain12,Borg Christophe6,Capitain Olivier7,Ferru Aurélie8,Bouché Olivier9,Lecomte Thierry12,Ternant David34ORCID

Affiliation:

1. Inserm UMR 1069, Nutrition Croissance et Cancer Tours University Tours France

2. Department of Gastroenterology and Digestive Oncology CHRU de Tours Tours France

3. EA4245 Transplantation, Immunologie, Inflammation Tours University Tours France

4. Plateforme Recherche, Centre Pilote de suivi Biologique des traitements par Anticorps CHRU de Tours Tours France

5. PRC, INRAe UMR85, CNRS UMR7247 Tours University Nouzilly France

6. Department of Oncology CHU Besançon Besançon France

7. Department of Medical Oncology ICO Angers France

8. Department of Medical Oncology CHU de Poitiers Poitiers France

9. Department of Gastroenterology and Digestive Oncology CHU Reims Reims France

Abstract

AimsThe exposure‐response relationship of bevacizumab may be confounded by various factors, including baseline characteristics, time‐dependent target engagement and recursive relationships between exposure and response, requiring effective mitigation. This study aimed to investigate the exposure‐response relationships of bevacizumab in metastatic colorectal cancer (mCRC) patients while mitigating potential biases.MethodsBevacizumab pharmacokinetics was described using target‐mediated drug disposition modelling. Relationships between target kinetics, progression‐free (PFS) and overall (OS) survivals were assessed using joint pharmacokinetic and parametric hazard function models. Both prognostic‐driven and response‐driven potential biases were mitigated. These models evaluated the impact of increased antigen target levels, clearance and intensified dosing regimen on survival.ResultsEstimated target‐mediated pharmacokinetic parameters in 130 assessed patients were baseline target levels (R0 = 8.4 nM), steady‐state dissociation constant (KSS = 10 nM) and antibody‐target complexes elimination constant (kint = 0.52 day−1). The distribution of R0 was significantly associated with increased baseline concentrations of carcinoembryonic antigen, circulating vascular endothelial growth factor and the presence of extrahepatic metastases. Unbound target levels (R) significantly influenced both progression and death hazard functions. Increasing baseline target levels and/or clearance values led to decreased bevacizumab unbound concentrations, increased R levels and shortened PFS and OS, while increasing bevacizumab dose led to decreased R and longer survival.ConclusionThis study is the first to demonstrate the relationship between bevacizumab concentrations, target involvement and clinical efficacy by effectively mitigating potential sources of bias. Most of the target amount may be tumoural in mCRC. Future studies should provide a more in‐depth description of this relationship.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Imagining the severe asthma decision trees of the future;Expert Review of Respiratory Medicine;2024-08-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3